Acquisition of symptoms, onset, 217–218
Adaptation, developmental epidemiology, 248
Adolescence. See also Child and adolescent psychiatry
drug dependence, 498, 511, 534–539
first-onset mania, 450–451
National Comorbidity Survey-R Adolescent Survey, 353–354
Adolescent depression, risk factors, 398
Adoption studies, environment/gene interaction, 76–78
Adulthood, drug dependence, 539–541
Adverse effects, psychopharmacoepidemiology, 185–186
Affected relative pair method, linkage analysis, 87–88
Affective disorders. See also Bipolar disorder
bipolar disorder, 428
developmental epidemiology, 245–246
epidemiological data on, 418419
Affective state, depression, 657
Age at onset. See also Onset
cchild and adolescent psychiatry (mood disorders), 665
first-onset mania, 450
National Comorbidity Survey, baseline results, 347
psychiatric genetics, 103–107
Age differences:
alcohol and abuse, 462, 464, 469, 471
bipolar disorder, 437
cchild and adolescent psychiatry:
anxiety disorders, 679–680
mood disorders, 667
drug dependence, 511–516, 530–541
dysthymic disorder, 406
panic disorder, 409–410
schizophrenia, 372–373
Agoraphobia, 410–414
defined, 410–411
panic disorder and, 412–414
rates of, 411
AIDS, future directions, 197
Alcohol Dependence Syndrome (ADS), 467
Alcohol use and abuse, 459–477. See also Drug dependence; Substance abuse
alcoholism, 466–473
alternative models, 471–472
comorbidity, 472–473
correlates, 471
diagnosis and definitions, 466–468
genetics, 472
levels of causation, 202–203
population estimates, 468–469
prevalence, 469–471
drinking practices, 460–463
measurements, 460–461
population-based estimates, 460
prevalence, 461–463
overview, 459–460
problems, 463–466
definitions, 463–464
prevalence and correlates, 464–465
sociological/clinical viewpoints, 465–466
Alzheimer’s disease, 604
comorbidity, 614, 615
prevalence, 610–611
Amish study, bipolar disorder, 431
Amphetamines, geographic distribution, 486
Analysis of variance. See ANOVA analysis
Analytic studies (mental health services research), 169–172
costs, 170
payments, 170–171
sector interactions, 172
ANOVA analysis:
developmental epidemiology, analytic methods, 243
one-way, reliability statistics, 139–141
two-way, reliability statistics, 141–143
Antisocial behavior, developmental epidemiology, 247
Antisocial personality disorder, prevalence, 573, 576
Anxiety disorders, 407. See also Agoraphobia;
Child and adolescent psychiatry (anxiety disorders); Generalized anxiety disorder;
Panic disorder; Social phobia
comorbidity, child and adolescent psychiatry, 664–665
epidemiology of, 389, 419
future directions, 419–420
Anxiety Disorders Interview Schedule for Children, 675
Ascertainment, psychiatric genetics, 99–102. See also Sampling
Association measures. See Odds ratio
Association studies, psychiatric genetics, 95–98
Asymmetric errors, reliability, 137–138
Attention deficit-hyperactivity disorder (ADHD): comorbidity, mood disorders and, 665 first-onset mania, 451
Attributable risk: association measures, 79 major depression, 402–403
Attrition, natural history of psychopathology, 231–232
Autism, measles, mumps, and rubella (MMR) immunization and, 199
Autoimmune disease, schizophrenia, 374
Avoidant personality disorder, prevalence, 578

Beck Depression Inventory (BDI):
  criterion validity, 153–154
  symptom scales and schedules, 291, 304
Behavior genetics, drug dependence, 482
Benzodiazepine, adverse effects, psychopharmacoepidemiology, 185–186
Bezugsziffer (BZ) denominator, psychiatric genetics, 104–105
Bias, developmental epidemiology, case-control studies, 242
Binary judgments, reliability, 137–138
Bipolar disorder, 427–444
case definitions, 428–430
epidemiologic studies, 430–435
  Amish study, 431
cross-national studies of major depression and, 433
Epidemiologic Catchment Area (ECA) Study, 431–432
  incidence data, 434–435
  international perspective, 433–434
  National Comorbidity Survey (NCS), 432–433
  population-based, 430
  genetic studies, 440
  mental health service utilization, 439–440
  nosology, 428
  overview, 427
  psychiatric genetics, 102–103
  risk factors, 437–439
  subtypes, 435–437
    Bipolar II disorder, 435
    comorbidity, 436–437
cyclothymia, 435
  full bipolar spectrum, 435–436
Birth factors, schizophrenia, 375–377
Birth weight, IQ and, levels of causation, 204–205
Blinding, experimental study designs, 11
Borderline personality disorder, prevalence, 576–577
Calgary Depression Scale (CDS), criterion validity, 153
Cannabis:
  clinical features and case definitions, 488
  geographic distribution, 486
  schizophrenia, 377–378
  twin studies, 522–523
Case-control studies:
cohort studies, 19–23
case selection, 19–21
  controls selection, 21–23
developmental epidemiology, 241–242
  exposure measures in, 23–24
  odds ratio, 37
  uses of, 24–25
Case-crossover studies, cohort studies, 23
Case registries, schizophrenia, 366
Case selection, case-control studies, cohort studies, 19–21
Catechol-o-methyltransferase (COMT), drug dependence, 520
Categorized data analysis. See Odds ratio
Causation. See Etiology; Levels of causation
Censoring:
cumulative incidence, outcome occurrence measures, 5
  natural history of psychopathology, 232–233
Center for Epidemiologic Studies - Depression (CES-D):
criterion validity, 153–156
diagnostic interviews, 261
geriatric psychiatry, 604, 608, 610, 612
  symptom scales and schedules, 291, 302, 304
Chain of psychiatric genetic research. See Psychiatric genetics
Chart review/records, personality disorders, data sources, 586
Child and Adolescent Psychiatric Assessment (CAPA), 633–634
Child and adolescent psychiatry, 629–655. See also Adolescence
classification and measurement, 630–638
categorical assessments, 631–634
dimensional assessments, 636–637
  harm to children, 637–638
  instrument selection, 634–636
  overview, 629–630
  population-based studies, 639–646
    Great Smoky Mountain Study, 641–642
    Isle of Wight/Inner Borough Study, 639–640
    methodology, 642–643
    National Comorbidity Survey, 641
    Ontario Child Health Study, 640
    Project on Human Development in Chicago Neighborhoods, 643–644
  risk factors, 646–650
  genetics, 646–647
  neighborhood and social context, 649–650

Bezugsziffer (BZ) denominator, psychiatric genetics, 104–105
Bias, developmental epidemiology, case-control studies, 242
Binary judgments, reliability, 137–138
Bipolar disorder, 427–444
case definitions, 428–430
epidemiologic studies, 430–435
  Amish study, 431
cross-national studies of major depression and, 433
Epidemiologic Catchment Area (ECA) Study, 431–432
  incidence data, 434–435
  international perspective, 433–434
  National Comorbidity Survey (NCS), 432–433
  population-based, 430
  genetic studies, 440
  mental health service utilization, 439–440
  nosology, 428
  overview, 427
  psychiatric genetics, 102–103
  risk factors, 437–439
  subtypes, 435–437
    Bipolar II disorder, 435
    comorbidity, 436–437
cyclothymia, 435
  full bipolar spectrum, 435–436
Birth factors, schizophrenia, 375–377
Birth weight, IQ and, levels of causation, 204–205
Blinding, experimental study designs, 11
Borderline personality disorder, prevalence, 576–577
Calgary Depression Scale (CDS), criterion validity, 153
Cannabis:
  clinical features and case definitions, 488
  geographic distribution, 486
  schizophrenia, 377–378
  twin studies, 522–523
Case-control studies:
cohort studies, 19–23
case selection, 19–21
  controls selection, 21–23
developmental epidemiology, 241–242
  exposure measures in, 23–24
  odds ratio, 37
  uses of, 24–25
Case-crossover studies, cohort studies, 23
Case registries, schizophrenia, 366
Case selection, case-control studies, cohort studies, 19–21
Catechol-o-methyltransferase (COMT), drug dependence, 520
Categorized data analysis. See Odds ratio
Causation. See Etiology; Levels of causation
Censoring:
cumulative incidence, outcome occurrence measures, 5
  natural history of psychopathology, 232–233
Center for Epidemiologic Studies - Depression (CES-D):
criterion validity, 153–156
diagnostic interviews, 261
  geriatric psychiatry, 604, 608, 610, 612
  symptom scales and schedules, 291, 302, 304
Chain of psychiatric genetic research. See Psychiatric genetics
Chart review/records, personality disorders, data sources, 586
Child and Adolescent Psychiatric Assessment (CAPA), 633–634
Child and adolescent psychiatry, 629–655. See also Adolescence
classification and measurement, 630–638
categorical assessments, 631–634
dimensional assessments, 636–637
  harm to children, 637–638
  instrument selection, 634–636
  overview, 629–630
  population-based studies, 639–646
    Great Smoky Mountain Study, 641–642
    Isle of Wight/Inner Borough Study, 639–640
    methodology, 642–643
    National Comorbidity Survey, 641
    Ontario Child Health Study, 640
    Project on Human Development in Chicago Neighborhoods, 643–644
  risk factors, 646–650
  genetics, 646–647
  neighborhood and social context, 649–650
parental psychopathology, 647
prenatal factors, 648–649
socioeconomic status, 647–648
Child and adolescent psychiatry (anxiety disorders), 674–86. See also Adolescence
comorbidity, 678–679
consequences, 686
definitions and assessment, 674–675
magnitude, 675–678
mood disorders and, 686–687
age differences, 679–680
autonomic and psychophysiological reactivity, 683–684
gender differences, 679
genetics and family history, 680–681
life events and stressors, 684–685
medical conditions, 682–683
perinatal influences, 682
socioeconomic status and ethnicity, 680
temperament and personality, 686–682
Child and adolescent psychiatry (mood disorders), 657–674. See also Adolescence
anxiety disorders and, 686–687
comorbidity, 664–665
consequences, 673
definition and assessment, 657–658
historical perspective, 657
magnitude of, 658–659
persistence, 672–673
rates of disorder, 659–661
rates of symptoms and syndromes, 661–664
risk factors, 666–672
age differences, 667
cognitive factors, 671
genetic differences, 666–667
genetics, 668–670
hormonal change, 670
life events and stressors, 671–672
neurobiology, 670
socioeconomic class, race, and ethnicity, 667–668
temperament, 670–671
treatment, 673–674
Child Behavior Checklist (CBCL), 451, 636–637
Childhood:
drug dependence, 530–534
first-onset mania, 450–451
schizophrenia, 375–377
Chi-squared statistic, tests of association, 37–39, 41, 42
Chlorpromazine, psychopharmacoeconomics, 181
Cholesterol, geriatric psychiatry, 612–613
Chromosome locus, psychiatric genetics, 79. See also Gene location
Chronic Disease Era, 197
Cirrhosis, alcoholism, 469
Clinical interview, personality disorders, data sources, 586–587. See also Psychiatric interview
Clinical Interview Schedule (CIS):
diagnostic interviews, 260
reliability and validity, 308–309, 310
symptom scales and schedules, 300, 306–307
Clinical model, sociological model and, alcohol use and abuse, 465–466
Clinician-administered structured interviews, reliability and validity, 311
Cluster sampling, survey sampling, 15
Cocaine:
abuse diagnosis, 505
clinical features and case definitions, 488, 492
geographic distribution, 487
twin studies, 522
Coefficient alpha, statistical remedies for low reliability, 136
Cognitive factors, child and adolescent psychiatry
(mood disorders), 671
Cohen’s 6, reliability statistics, 144
Coefficient criterion, internal validity, 159
Cohort studies, 16–25
case-cohort studies, 23
case-control studies, 19–23
case selection, 19–21
controls selection, 2–23
exposure measures in, 23–24
uses of, 24–25
case-crossover studies, 23
developmental epidemiology, 240–241
major depression, 396–397
odds ratio, 35–37
prospective, 16–17
retrospective, 18–19
Community studies, schizophrenia, 367–368
Comorbidity:
agoraphobia, 413
alcoholism, 472–473
anxiety disorders, 407
bipolar disorder, 436–437
child and adolescent psychiatry:
anxiety disorders, 678–679, 686–687
mood disorders, 664–665, 686–687
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 339–340
geriatric psychiatry, 614–615
major depression, 401–402
National Comorbidity Survey, 343–362. (See also National Comorbidity Survey (NCS))
outcome, 228–230
personality disorders, 591–592
Complete ascertainment, psychiatric genetics, 100
Composite International Diagnostic Interview (CIDI). See also World Health Organization (WHO)
(CIDI) (Continued)
bipolar disorder, 433, 434
talk and adolescent psychiatry, 645
diagnostic interviews, 263–264, 344–345
drug dependence, 492, 493, 502–505
geriatrie psychiatry, 604
major depression, 391–392
National Comorbidity Survey, 354
panic disorder, 409
social phobia, 415
symptom scales and schedules, 294, 295, 296, 298, 299, 301, 303, 306–307
validity and reliability, 309
WHO World Mental Health 2000, 355–357
Concordance, twin studies, 74
Concurrent validity, criterion validity, 152–153
Conduct disorder, comorbidity, mood disorders and, 665
Confounding bias, nonexperimental (observational) studies, group comparisons in, 28–30
Consensus rule, reliability, 137
Consistency of association, internal validity, 159
Construct validity, 156–158
application of, 157–158
described, 156–157
threats to, 158
Content validity: described, 150–151
examples of, 151–152
Contextual level:
individual level combined with, 202–203
levels of causation, 200–202
Cornell Medical Index (CMI), 287, 299, 300, 302
Cornell Selectee Index (CSI), 286, 287
Costs. See also Health Maintenance Organizations (HMOs)
child and adolescent psychiatry, instrument selection, 635
geriatrie psychiatry, 620
mental health services research, 165
mental health services research, analytic studies, 170
psychopharmacoepidemiology, 188
Course of disease, 224–228. See also Pathologic process
bipolar disorder, 428
drug dependence, 496–500
first-onset mania, 454
recurrence, 226–228
remission, 224–226
schizophrenia, 378–379
Criminal justice system, drug dependence, 494, 517
Criterion validity: described, 152–153
examples of, 153–156
Cronbach’s:
content validity, 152
reliability statistics, 143
symptom scales and schedules, 307, 309
Cross-sectional assessments, criterion validity, 152–153
Cross-sectional studies, 12–16
disease and exposure status measures, 15–16
odds ratio, 35–36
survey sampling, 13–15
Cultural factors:
alcohol use and abuse, 459
bipolar disorder, 439
Cumulative incidence, outcome occurrence measures, 56
Cyclothymia, bipolar disorder, 435
Cytogenic abnormalities, psychiatric genetics, 99
Data hierarchies, developmental epidemiology, analytic methods, 243–244
Data sources: personality disorders, 585–589
psychopharmacoepidemiology, 183–185
Dementia praecox, 428, 445
Dementing disorders: comorbidity, 614–615
outcome studies, 617–619
prevalence, 610–611
risk factors, 613–614
Demography (schizophrenia), 370–373. See also Risk factors; specific risk factors
gender and age, 372–373
marital status, 373
race and ethnicity, 371–372
social class, 370–371
Department Interview, diagnostic interviews, 261–262
Dependent personality disorder, prevalence, 578, 580
Depression. See also Child and adolescent psychiatry (mood disorders); Dysthymic disorder; Major depression
developmental epidemiology, 245–246
epidemiology of, 389, 418–419
geriatrie psychiatry, 604–605
comorbidity, 614–615
depressive disorders, 608–609
etiologic studies, 612–613
outcome studies, 615–617
subsyndromal depression, 609–610
Descriptive studies (mental health services research):
institution surveys, 166–167
population surveys, 167–169
Determinants of Outcome of Severe Mental Disorders (DOSMED), 367, 369
Developmental epidemiology, 239–255
analytic methods, 242–244
data hierarchies, 243–244
growth curve models, 243
missing values, 244
repeated observations, 243
applications, 244–248
affective disorder, 245–246
post-traumatic stress disorder (PTSD), 246–247
schizophrenia, 244–245
temperament, adaptation and resilience, 248
violence, 247
defined, 239
developmental psychopathology and, 240
study design strategies, 240
cohort studies, 240

Developmental issues:
personality disorders, 567–568
psychopathology, developmental epidemiology, 240

Diabetes, schizophrenia and, 374

Diagnostic and Statistical Manual of Mental Disorders (DSM):
onset, 216
reliability, 131

Diagnostic and Statistical Manual of Mental Disorders (DSM-I):
personality disorders, 564, 573
perspective of, 334
symptom scales and schedules, 284, 285

Diagnostic and Statistical Manual of Mental Disorders (DSM-II), perspective of, 334

Diagnostic and Statistical Manual of Mental Disorders (DSM-III):
agoraphobia, 410411, 412, 413, 414
alcoholism, 467, 468, 469–471
anxiety disorders, 407
bipolar disorder, 431, 433
child and adolescent psychiatry, 631, 632, 633, 634, 641, 642, 648, 675, 678
diagnostic interviews, 262–263, 333, 344
drug dependence, 488, 489, 491, 492, 502–505, 513, 514, 530, 531, 540
dysthymic disorder, 404–405
first-onset mania, 450, 451
generalized anxiety disorder, 415–417
geriatric psychiatry, 605, 609, 610
major depression, 390, 391, 395, 396, 399, 401, 403–404
National Comorbidity Survey, 347
obsessive-compulsive disorder, 417–418
onset, 220
outcome, 229
panic disorder, 408, 409
personality disorders, 563, 564, 565–566, 568, 569, 570–581, 584, 588, 590
perspective of, 335, 336

population surveys, mental health services research, 168
schizophrenia, 367, 368
social phobia, 414–415
symptom scales and schedules, 275, 278, 284, 285, 290, 293, 297, 305, 311, 312

Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R):
agoraphobia, 410–411, 412
alcoholism, 467, 468, 470–471
anxiety disorders, 407
bipolar disorder, 433
child and adolescent psychiatry, 631, 632, 633, 634, 641, 642, 648, 675, 678
criterion validity, 154–156
drug dependence, 490, 492, 502–505, 507
dysthymic disorder, 404–405
first-onset mania, 449, 451, 454
generalized anxiety disorder, 415–417
geriatric psychiatry, 604, 608, 610
major depression, 390, 391, 395, 396, 403–404
National Comorbidity Survey, 346, 348–349, 350
panic disorder, 408, 409
personality disorders, 564, 566, 567, 570, 573–576, 578, 579, 588
perspective of, 336
population surveys, mental health services research, 168
schizophrenia, 368, 369, 374
social phobia, 414–415
symptom scales and schedules, 275, 293, 298, 305

Diagnostic and Statistical Manual of Mental Disorders (DSM-IV):
agoraphobia, 412
alcoholism, 467–468
bipolar disorder, 428–430
child and adolescent psychiatry, 631, 632, 633, 634, 642, 645, 674, 675, 678
diagnostic interviews, 264–265
drug dependence, 491, 522
first-onset mania, 446–447
future trends, 340–341
geriatric psychiatry, 604, 608
historical perspective, 333–336
impact of, 336–340
clinical significance requirement, 338–339
comorbidity, 339–340
generally, 336–337
specific wording of criteria, 338
symptom counts, 337–338
major depression, 395, 398
mood disorders, 658
National Comorbidity Survey, 352
overview, 333
panic disorder, 409
incidence, 500–501
overview, 479–483
pathogenesis, natural history, and clinical
course, 496–500
prevalence, 502–508
problem distribution, 483–488
treatment, 541–542
Duchenne’s muscular dystrophy, psychiatric
genetics, 99
Dysthymic disorder, 404–407
defined, 404
risk factors, 405–406

Ecogenetics, segregation analysis, 113
Economy, mental health services research, 165.
See also Costs
Ecstasy (drug), 481
Education level, alcohol use and abuse, 462, 465, 471
Effectiveness, mental health services research, 165–166, 172–174
Efficiency, mental health services research, 165
Emergence of symptoms, onset, 218–219
Emerging trends. See Future directions
Environment:
child and adolescent psychiatry, 649–650
psychiatric genetics, 65–66
Environment/gene interaction:
adoption studies, 76–78
segregation analysis, 113–114
twin models, 80
twin studies, 74–76
Epidemiologic Catchment Area (ECA) Study, 344
agoraphobia, 411, 412, 413, 414
alcoholism, 469, 470, 471, 472
bipolar disorder, 431–432, 436, 438, 439
child and adolescent psychiatry, 664
drug dependence, 491–492, 493, 501, 502–505,
507, 510, 512, 514, 540, 541
dysthymic disorder, 404–405
generalized anxiety disorder, 416
geriatric psychiatry, 605–607, 613, 616, 618, 619
major depression, 391, 392, 393, 394, 397, 399,
400, 401, 403
panic disorder, 409–410
personality disorders, 565, 573, 576, 592
Epidemiologic research methods, 333. See also
Psychiatric epidemiologic research methods
Epidemiology, defined, 3. See also Psychiatric
epidemiologic research methods;
Psychopharmacoepidemiology
Equity, mental health services research, 165
Established Populations for Epidemiologic Studies
of the Elderly (EPESE), 608, 610, 611, 612,
613, 615, 618
Estimation, reliability, 133–135
Ethnicity. See also Race differences
alcohol use and abuse, 462, 463, 464, 469–470, 471
child and adolescent psychiatry:
anxiety disorders, 680
mood disorders, 667–668
major depression, 399
panic disorder, 410
schizophrenia, 371–372
Ethnography, drug dependence, 481
Etiology:
geriatric psychiatry, 611–615
pathologic process and, onset, 216–219
Experimental studies:
mental health services research, 172–174
study designs, 10–12
Exposure, psychiatric genetics, 66
Exposure measures, case-control studies, 23–24
Exposure status measures, cross-sectional studies, 15–16
External validity, described, 160–161
Extra-medical drug use, described, 480
Familial disorders, 6673. See also Genetics
family study versus family history, 70–73
proband selection, 67–70
Family history:
child and adolescent psychiatry:
anxiety disorders, 680–681
mood disorders, 669–670
major depression, 402
panic disorder, 410
schizophrenia, 373–374
Family-study designs, psychiatric genetics, 107–109
Family study/history, psychiatric genetics, 70–73
First-onset mania, 445–458
age at onset, 450
children and adolescents, 450–451
clinical features, 452–453
course of disease, 454
diagnosis and definitions, 445–447
diagnostic stability, 454–455
gender differences, 451
genetics and migration, 451–452
incidence, 447–450
overview, 445
substance abuse, 453–454
Fisher’s exact test, tests of association, 40, 41, 42
Fluorescent in situ hybridization (FISH), psychiatric genetics, 99
Folie circulaire, 428. See also Bipolar disorder
Food and Drug Administration (FDA), 182
Forensic psychiatry, drug dependence, 494
Functioning, outcome, 230
Future directions, 195–211

Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 340–341
drug dependence, 543–545
historical perspective, 196–197
levels of causation, 198–206
combining levels, 202–203
contextual level, 200–202
examples, 203–206
individual level, 198–200
logic extended, 206–207
mood and anxiety disorders, 419–420
overview, 195–196
personality disorders, 592
possibilities, 207–208
psychiatric interview, 270
psychopharmacoeconomics, 189–190
schizophrenia, 380
Gateway association, drug dependence, 498
GEMINI, segregation analysis algorithms, psychiatric genetics, 111
Gender differences:
alcohol use and abuse, 461–462, 464, 465, 468, 469, 470–471
bipolar disorder, 438
child and adolescent psychiatry:
anxiety disorders, 679
mood disorders, 666–667
drug dependence, 510–511
dysthymic disorder, 406
first-onset mania, 451
major depression, 395–396
panic disorder, 409
schizophrenia, 372–373
Gene chips, gene location, 86
Gene/environment interaction, twin studies, 74–76
Gene location, 82–99
DNA biosensors and gene chips, 86
linkage analysis, 83–86
alternatives to, 95–99
background of, 83–84
genetic markers for, 84–86
statistical methods of, 86–94
mode of transmission, psychiatric genetics, 79
General Health Questionnaire (GHQ):
diagnostic interviews, 260
reliability and validity, 308–309
symptom scales and schedules, 300–301, 303, 304, 305, 306
Generalizability theory, reliability estimation, 135
Generalized anxiety disorder, 415–417
child and adolescent psychiatry, 674, 675
defined, 415–416
rates of, 416–417
risk factors, 417
Genetic counseling, psychiatric genetics, 78
Genetic disorders, gene location, 83
Genetic markers, linkage analysis, 84–86
Genetics. See also Psychiatric genetics
  alcoholism, 472
  bipolar disorder, 440
  child and adolescent psychiatry, 646–647
  anxiety disorders, 680–681
  mood disorders, 666–670
  drug dependence, 482, 518–528
  geriatric psychiatry, 613, 614
  levels of causation, 202–203
  major depression, 402
  panic disorder, 410
  schizophrenia, 373–374
Genome, composition of, 82
Genotype, psychiatric genetics, 66
Geography:
  drug dependence, 483–488, 503
  first-onset mania, 451–452
Geriatric depression, risk factors, 397–398
Geriatric psychiatry, 603–628
  case definition, 604–605
  case distribution, 605–611
  dementing disorders, 610–611
  depressive disorders, 608–609
  subsyndromal depression, 609–610
etiolic studies, 611–615
  comorbidity, 614–615
  dementing disorders, 613–614
  depression, 612–613
  health care system, 620
  historical perspective, 619–620
  outcome studies, 615–619
  dementing disorders, 617–619
  depressive disorders, 615–617
  overview, 603–604
Goodness of fit, psychiatric genetics, 79
Government databases,
  psychopharmacoepidemiologic data sources, 183–184
Grade of Membership (GOM) analysis, 309
Great Smoky Mountain Study of Youth, 641–642
Group comparisons, nonexperimental
  (observational) studies, 26–30
Growth curve models, developmental
  epidemiology, analytic methods, 243

Hamilton Rating Scale, 304
Haplotypes, linkage analysis, 85
Hardy-Weinberg equilibrium, linkage analysis, 90–91, 112
Hawthorne effect, experimental study designs, 10–11
Health care system, geriatric psychiatry, 620
Health maintenance organizations (HMOs). See also Costs
mental health services research, payments, 171
  psychopharmacoepidemiology, data sources, 184
Health Opinion Survey (HOS), 288, 289, 290, 291
  diagnostic interviews, 260
  symptom scales and schedules, 300
Heritability, twin studies, 74–75. See also
  Genetics; Twin studies
Heroin, geographic distribution, 484–485
Heterozygous gene, linkage analysis, 93
High-risk design, psychiatric genetics, 108–109
History effects, internal validity, 159
Histrionic personality disorder, prevalence, 577–578
Home Inventory Schedules (HIS), prevalence
  assessment, 259–260
Homelessness, bipolar disorder, 439
Homologous chromosomes, linkage analysis, 83–84
Homozgyous gene, phenylketonuria (PKU), 75
Hopkins Symptom Checklist (HSCL), 303, 304, 308
Hormonal change, child and adolescent
  psychiatry, 670
Hospital records, psychiatric epidemiology, 257–258
Household informant, psychiatric epidemiology, 258
Hybrid studies, nonexperimental (observational)
  studies, 25–26
Hypothalamic-pituitary-adrenal (HPA) system,
  depression, 246

Ice. See Methamphetamine
Identity-by-descent method, linkage analysis, 92
Identity-by-state method, linkage analysis, 92
Imipramine, psychopharmacoepidemiology, 181
Incidence:
  drug dependence, 500–501
  first-onset mania, 447–450
  population measures of onset, 22–224
Incidence density, outcome occurrence measures, 45
Individual level:
  contextual level combined with, 202–203
  levels of causation, 198–200
Infectious Disease Era, 196–197
Informants, personality disorders, data sources, 586
Information bias, nonexperimental (observational)
  studies, group comparisons in, 27–28
Inner Borough Study, 639–640
Institution surveys, mental health services
  research, descriptive studies, 166–167
Instrumentation effects, internal validity, 159
Intensification of symptoms, onset, 217–218
Internal consistency, reliability estimation, 134–135
Internal validity, described, 158–160
International Classification of Diseases (ICD). See also World Health Organization (WHO)
   alcoholism, 468
   bipolar disorder, 434
   child and adolescent psychiatry, 633
diagnostic criteria, 335, 336, 338
   drug dependence, 489, 490–491
   first-onset mania, 446, 447, 449–450, 454
   geriatric psychiatry, 608, 610
   major depression, 392–393, 404
   National Comorbidity Survey, 353
   personality disorders, 569, 588–589
   symptom scales and schedules, 283, 296, 307
International Personality Disorders Examination (IPDE, WHO), 298, 587
Interval prevalence, drug dependence, 506–507
Interviews. See Psychiatric interview
Intraclass correlations, reliability statistics, 138–139
   Iowa Structured Psychiatric Interview (ISPI), 292, 296
   Iowa 500 Study, 292
IQ, birth weight and, levels of causation, 204–205
   Isle of Wight/Inner Borough Study, 639–640
Item Response Theory (IRT), 277–278
Jails, mental health services research, institution surveys, 167
Kaplan-Meier method, psychiatric genetics, 106–107
Karyotype, psychiatric genetics, 99
Large sample test of equal proportions, 40
Lay-administered diagnostic schedules, reliability and validity, 309–311
Levels of causation, 198–206. See also Etiology combining levels, 202–203
   contextual level, 200–202
   individual level, 198–200
Liability concept, psychiatric genetics, mode of transmission, 80–81
Life events:
   child and adolescent psychiatry (mood disorders), 671–672
   risk factors, child and adolescent psychiatry (anxiety disorders), 684–685
Lifetime prevalence. See also Prevalence
drug dependence, 502–506
   National Comorbidity Survey (baseline), 345–347
outcome occurrence measures, 67 (See also Developmental epidemiology)
   Lifetime risk, psychiatric genetics, 104. See also Developmental epidemiology
Likelihood, psychiatric genetics, mode of transmission, 79
Linkage analysis, 83–86
   alternatives to, 95–99
   background of, 83–84
   genetic markers for, 84–86
   statistical methods of, 86–94
Liver cirrhosis, alcoholism, 469
Lod score method, linkage analysis, 88–91
Logistic regression, odds ratio, 58–63
Longitudinal Aging Study Amsterdam (LASA), 608, 610, 612, 618
Loss to follow-up, cumulative incidence, outcome occurrence measures, 5
Lundby interview, diagnostic interviews, 260–261, 262
Major depression, 390–404
   defined, 390
   ECA follow-up, 394
   geriatric psychiatry, 609
   paradigms of, 394–395
   rates of, 390–393
   risk factors, 395–403
   adolescent depression, 398
   attributable risk, 402–403
   comorbidity, 401–402
   family history, 402
   gender differences, 395–396
   geriatric depression, 397–398
   marital status, 401
   race and ethnicity, 399
   secular/temporal effects, 396–397
   socioeconomic status, 399–400
   urban-rural residence, 400
   subtypes, 393
   Matched-pairs analysis, odds ratio, 56–58
   Managed care, geriatric psychiatry, 620. See also Costs; Health Maintenance Organizations (HMOs)
   Mania. See First-onset mania
   Manic-depressive illness. See Bipolar disorder
   MANOVA, developmental epidemiology, 243
   Mantel-Haenszel test, 49–51, 56, 58
   Marijuana. See Cannabis
   Marital status:
      alcohol use and abuse, 462, 464, 470, 471
      bipolar disorder, 438–439
      dysthymic disorder, 406
      major depression, 401
      schizophrenia, 373
      Matching fallacy, psychiatric genetics, 68
Mathematical modeling, psychiatric genetics, mode of transmission, 79–80
Maturation, internal validity, 159
Maudsley Personality Inventory (MPI), 286, 287, 288, 289
MAXFUN, segregation analysis algorithms, psychiatric genetics, 111
Maximum likelihood estimate (MLE), psychiatric genetics, 105
McNemar’s test, 57
Measles, mumps, and rubella (MMR) immunization, autism and, 199
Medical Outcomes Study (MOS), 301
Medication. See Psychopharmacoepidemiology; Psychopharmacology
Meiosis, linkage analysis, 83–84
Mendelian genetic model: linkage analysis, 91
Mode of transmission, psychiatric genetics, 78–82
Mental health services research, 165–179
analytic studies, 169–172
costs, 170
payments, 170–171
sector interactions, 172
descriptive studies, 166–169
institution surveys, 166–167
population surveys, 167–169
experimental studies, 172–174
questions in, 165–166
Mental health service utilization, bipolar disorder, 439–440
Mental Status Schedule (MSS), 304
Methamphetamine, 481
Methylenedioxymethamphetamine (MDMA), 481
Midtown Manhattan study, 259, 289, 290, 564
Migration, first-onset mania, 451–452
Mini-Mental State Exam (MMSE), geriatric psychiatry, 604
Minisatellites, linkage analysis, 85–86
Minnesota Multiphasic Personality Inventory (MMPI), 258, 259, 286, 289, 302
Minor depression, geriatric psychiatry, 610
Minority groups, mental health services research: institution surveys, 167
population surveys, 167–169
Missing values, developmental epidemiology, analytic methods, 244
Mixed model, psychiatric genetics, mode of transmission, 82
Mode of transmission, psychiatric genetics, 78–82
Monoamine oxidase A (MAOA), drug dependence, 520–521
Mono-operations bias, construct validity, 158
Monozygotic twins. See also Twin studies
family-study designs, 107–108
gene/environment interaction, 74–76
major depression, 402
psychiatric genetics, 66
schizophrenia, 373
Mood disorders. See also Anxiety disorders;
Bipolar disorder; Child and adolescent psychiatry (mood disorders); Dysthymic disorder; Major depression
adoption studies, 77
bipolar disorder, 428–430
epidemiology of, 389
future directions, 419–420
psychiatric genetics, mode of transmission, 81
twin studies, 75–76
Morbidity:
incidence density, outcome occurrence measures, 45
risk of, psychiatric genetics, 103–106
Mortality:
drug dependence, 499, 508–509
geriatric psychiatry:
dementing disorders, 618–619
depression, 615–617
incidence density, outcome occurrence measures, 45
outcome, 230
Mortality effects, internal validity, 160
Multifactorial polygenic model, psychiatric genetics, mode of transmission, 80–82
Multiple ascertainment, psychiatric genetics, 101
Multistage studies, hybrid studies, 25–26
Muscular dystrophy, Duchenne’s, psychiatric genetics, 99
Mutation screening, psychiatric genetics, 98–99
Narcissistic personality disorder, prevalence, 578
National Comorbidity Survey (NCS), 294–296, 298, 310, 343–362
agoraphobia, 411, 412
alcoholism, 469, 470, 473
baseline background and design, 344–345
baseline results, 345–351
age at onset, 347
comorbidity, 347–348
lifetime and recent prevalences, 345–347
primary and secondary disorders, 348–350
primary prevention of secondary disorders, 351
pure and comorbid lifetime disorders, 348
service utilization, 350–351
social costs, 350
bipolar disorder, 432–433, 436, 438
child and adolescent psychiatry, 641, 645, 659
drug dependence, 492, 493, 502–505, 507, 514, 515
dysthymic disorder, 404
generalized anxiety disorder, 416
major depression, 391, 396, 398, 399, 400, 401–402
NCS-2, design and rationale, 351–352
NCS-R:
Adolescent Survey, 353–354
design and rationale, 352–353
overview, 343, 357–358
personality disorders, 592
schizophrenia, 368
social phobia, 414–415

WHO World Mental Health 2000, 355–357
calibrating CIDI diagnoses, 357
clinical significant impairment, 356
comparative impairments, 357
recent prevalence and severity, 355–356

National Institute of Mental Health (NIMH), 335, 336, 632, 642, 658
National Institute of Neurologic, Communicative Diseases and Stroke—Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA), geriatric psychiatry, 604

National Institute on Alcohol Abuse and Alcoholism (NIAAA), 336, 507
National Institute on Drug Abuse (NIDA), 336
National Longitudinal Alcohol Epidemiology Study (NLAES),
drug dependence, 492, 502, 527
Natural history of psychopathology, 215–238
course of disease, 224–228
recurrence, 226–228
remission, 224–226
drug dependence, 496–500
methodology, 231–234
attrition, 231–232
censoring, 232–233
recall bias, 233–234
onset, 216–224
etiologic and pathologic processes, 216–219
population measures, 222–224
prodromes and precursors, 219–222
outcome, 228–230
overview, 215–216

Neighborhood factors, child and adolescent psychiatry, 649650.
See also Environment

Nestled case-control studies, developmental epidemiology, 242

Neurobiology:
alcoholism, 472
child and adolescent psychiatry (mood disorders), 670

Neuropsychiatric Screening Adjunct (NSA): prevalence assessment, 259
symptom scales and schedules, 286–288, 291, 300, 303

Neurotransmitters, drug dependence, 519–520
Nomologic network, construct validity, 156–157
Nonaffective acute remitting psychosis, levels of causation, 204

Nonexperimental (observational) studies, 12–30
cohort studies, 16–25
case-control studies, 19–25
prospective, 16–17
retrospective, 18–19
cross-sectional studies, 12–16
disease and exposure status measures, 15–16
survey sampling, 13–15
group comparisons in, 26–30
confounding bias, 28–30
information bias, 27–28
selection bias, 27
hybrid studies, 25–26

Novel populations, reliability, 131–132
Nucleotides, linkage analysis, 85
Null hypothesis:
chi-squared statistic, tests of association, 37–39
Mantel-Haenszel test, 49–51

Observational studies. See Nonexperimental (observational) studies

Obsessive-compulsive personality disorder, 417–418
defined, 417
prevalence, 581
rates of, 417
risk factors, 417

Obstetric factors, schizophrenia, 375377.
See also Prenatal influences

Odds ratio, 35–63
association measures, 79, 43–46
inference for multiple 2 x 2 tables, 49–56
inference for single 2 x 2 table, 46–49
logistic regression, 58–63
matched-pairs analysis, 56–58
outcome occurrence measures, 79
overview, 35–37
tests of association, 37–43

Oldest old, defined, 603
Oligogenic model, psychiatric genetics, mode of transmission, 80

One-way ANOVA analysis, reliability statistics, 139–141

Onset, 216224.
See also Age at onset
etiologic and pathologic processes, 216–219
population measures of, 222–224
prodromes and precursors, 219–222

Ontario Child Health Study, 640
Ontario Mental Health Survey, 298

Opium, geographic distribution, 484–485

Outcome, 228–230
outcome occurrence measures, 49
association measures, 79
cumulative incidence, 56
incidence density, 45
prevalence, 67

Outpatients, psychiatric epidemiology, 258
OxyContin, 479, 480–481
Pairwise concordance, twin studies, 74
Panel studies, hybrid studies, 26
Panic disorder. See also Anxiety disorders
agoraphobia and, 412–414
defined, 408
rates of, 409
risk factors, 409–410
Paranoid personality disorder, prevalence, 570
Parental psychopathology, child and adolescent
psychiatry, 647
Path analysis, psychiatric genetics, mode of
transmission, 81–82
Pathologic process. See also Course of disease
drug dependence, 496–500
etiologic process and, onset, 216–219
Patient adherence, psychopharmacoepidemiology,
187–188
Patient Health Questionnaire (PHQ), 301, 306
Payments, mental health services research,
analytic studies, 170–171
Pearson correlation, reliability statistics, 145
Penetrance, psychiatric genetics, mode of
transmission, 79
Perinatal influences:
child and adolescent psychiatry, 648–649
certainty issues, 682
drug dependence, 528–530
Period prevalence rate, outcome occurrence
measures, 67
Persistence:
child and adolescent psychiatry (anxiety
disorders), 685–686
certainty issues, 672–673
Personal Health Questionnaire (PHQ), 301
Personality Assessment Schedule (PAS),
personality disorders, 566
Personality Diagnostic Questionnaire (PDQ),
personality disorders, 566, 588
Personality disorders, 563–599
comorbid, 591–592
certainty issues, 581–584
developmental issues, 567–568
future directions, 592
methodological issues, 584–592
overview, 563–564
prevalence, 564–567
antisocial personality disorder, 573, 576
avoidant personality disorder, 578
borderline personality disorder, 576–577
dependent personality disorder, 578, 580
histrionic personality disorder, 577–578
narcissistic personality disorder, 578
obcessive-compulsive personality disorder, 581
paranoid personality disorder, 570
schizoid personality disorder, 570
schizotypal personality disorder, 572–573
treated prevalence, 569–570
Personality traits, defined, 563
Phenocopies, linkage analysis, 91–92, 93
Phenothiazines, bipolar disorder and, 428
Phenotype, psychiatric genetics, 66
Phenylketonuria (PKU), 583
gene location, 97
segregation analysis, 114
twin studies, 75
Placebo, experimental study designs, 10–11
POINTER, segregation analysis algorithms,
109–114
Point prevalence, drug dependence, 506–507
Polyomorphism information, linkage analysis, 85
Population-based studies:
alcohol use and abuse, 460
bipolar disorder, 430
child and adolescent psychiatry, 639–646
Great Smoky Mountain Study, 641–642
Isle of Wight/Inner Borough Study, 639–640
methodology, 642–643
National Comorbidity Survey, 641
Ontario Child Health Study, 640
Project on Human Development in Chicago
Neighborhoods, 643–644
developmental epidemiology, 242
Population measures, of onset, 222–224
Population surveys, mental health services
research, 167–169
Population variance, reliability and, 135
Post-dictive validity, criterion validity, 152
Post-traumatic stress disorder (PTSD),
developmental epidemiology, 246–247
Practice-based networks,
psychopharmacoepidemiology, data sources,
185
Precursors, prodromes and, onset, 219–222
Predictive validity. See Criterion validity
Prenatal influences:
child and adolescent psychiatry, 648–649
drug dependence, 528–530
schizophrenia, 375–377
Prescription guidelines,
psychopharmacoepidemiology, 187
Present State Examination (PSE):
bipolar disorder, 434
diagnostic interviews, 260
personality disorders, 566
symptom scales and schedules, 292, 296, 297,
298, 300, 304
Prevalence. See also Lifetime prevalence
alcohol use and abuse, 461–463, 464–465, 469–471
assessment of, psychiatric interview, 259–260
child and adolescent psychiatry:
  anxiety disorders, 675–678
  mood disorders, 658–664
  drug dependence, 502–508

geriatric psychiatry:
  dementing disorders, 610–611
  depressive disorders, 608–609
  subsyndromal depression, 609–610
  obsessive-compulsive personality disorder, 581
  outcome occurrence measures, 67
  personality disorders, 564–567
  antisocial personality disorder, 573, 576
  avoidant personality disorder, 578
  borderline personality disorder, 576–577
  dependent personality disorder, 578, 580
  histrionic personality disorder, 577–578
  narcissistic personality disorder, 578
  obsessive-compulsive personality disorder, 581
  paranoid personality disorder, 570
  schizoid personality disorder, 570
  schizotypal personality disorder, 57–573
  treated prevalence, 569–570
  schizophrenia, 368–369
  tobacco dependence, 50–506

Primary care populations:
  mental health services research, effectiveness, 173
  population surveys, mental health services research, 169

Primary prevention, of secondary disorders, National Comorbidity Survey, 351

Prisons, mental health services research, institution surveys, 167

Probability, odds ratio, 44–46

Proband selection:
  ascertainment bias, 100
  familial disorders, 67–70
  Probandwise concordance, twin studies, 74
  Prodsomes, precursors and, onset, 219–222

Product moment correlation, reliability statistics, 145

Program for Assertive Community Treatment (PACT), 174

Project on Human Development in Chicago Neighborhoods, 643–644

Prospective cohort studies:
  described, 16–17
  developmental epidemiology, 240–241
  odds ratio, 36–37

Protective factors, drug dependence, 483

Psychiatric Epidemiologic Research Instrument (PERI), 291, 292

Psychiatric epidemiologic research methods, 333.
  See also Nonexperimental (observational) studies

outcome occurrence measures, 49

association measures, 79
  cumulative incidence, 56
  incidence density, 45
  prevalence, 67
  overview, 34
  study designs, 926
  experimental studies, 10–12
    generally, 9–10
    nonexperimental (observational) studies, 12–26

Psychiatric epidemiology. See also Developmental epidemiology

developmental epidemiology, 239–255
future directions in, 195–211 (See also Future directions)

psychiatric genetics and, 115

Psychiatric genetics, 65–130. See also Genetics

familial disorders, 66–73
  family study versus family history, 70–73
  proband selection, 67–70
  gene/environment interaction, 73–78
  adoption studies, 76–78
  twin studies, 74–76
  gene location, 82–99 (See also Gene location)
  glossary for, 115–119
  methodology, 99–114
  ascertainment, 99–102
  family-study designs, 107–109
  risk estimation to relatives, 102–107
  segregation analysis algorithms, 109–114
  mode of transmission, 78–82
    mathematical modeling, 79–80
    model types, 80–82
  overview, 65–66

psychiatric epidemiology and, 115

Psychiatric interview, 257–271. See also specific interviews

child and adolescent psychiatry, harm to children, 637638

diagnostic interviews, 260–264
  Center for Epidemiological Studies - Depression (CESD), 261
  Clinical Interview Schedule / General Health Questionnaire (CIS/GHQ), 260
  Composite International Diagnostic Interview (CIDI), 263–264, 344–345
  Department Interview, 261–262
  Diagnostic Interview Schedule (DIS), 262–263
  Health Opinion Survey (HOS), 260
  Lundby interview, 260–261
  Present State Examination (PSE), 260
  psychopharmacoepidemiology, 261
  SADS-L, 262

future trends, 270

historical perspective, 257–258

personality disorders, 565, 586–587
Psychiatric interview (Continued)
prevalence assessment, 259–260
Home Inventory Schedules (HIS), 259–260
Neuropsychiatric Screening Adjunct (NSA), 259
psychometric properties, 265–270
reliability, 266
validity, 266–270
schizophrenia, 367–368
stability and innovation in, 264–265
Psychiatric medication. See
Psychopharmacoepidemiology; Psychopharmacology
Psychiatric Status Schedule (PSS), 304
Psychopathology. See Natural history of psychopathology
Psychopharmacoepidemiology, 181–194
clinical questions, 185–189
adverse effects, 185–186
cost analysis, 188
optimizing interventions, 188–189
patient adherence, 187–188
patterns, trends, and predictors, 186
prescription guidelines, 187
unmet needs assessment, 186–187
data sources, 183–185
government databases, 183–184
health maintenance organizations, 184
practice-based networks, 185
surveys, 184–185
diagnostic interviews, 261
future directions, 189–190
historical perspective, 181–182
study advantages, 182–183
Psychopharmacology:
bipolar disorder, 428
drug dependence, 541–542
geriatric psychiatry, 607
Psychosis. See also Schizophrenia
epidemiology of, 365–387
nonaffective acute remitting, levels of causation, 204
Psychotic affective disorder, schizophrenia and, 374
Quasi-experimental studies, internal validity, 159
Questionnaires:
psychiatric epidemiology, 258
reliability estimation, 134
Race differences. See also Ethnicity
alcohol use and abuse, 462, 463, 464, 469–470, 471
bipolar disorder, 438
child and adolescent psychiatry:
anxiety disorders, 680
mood disorders, 667–668
drug dependence, 516–518
dysthymic disorder, 406
major depression, 399
panic disorder, 410
schizophrenia, 371–372
Randomization, experimental study designs, 10
Randomized clinical trial, experimental study designs, 112
Random sampling, reliability and, 135
Rating scales, personality disorders, data sources, 589
Recall bias:
developmental epidemiology, case-control studies, 242
natural history of psychopathology, 233–234
Recessive gene, phenylketonuria (PKU), 75
Recombination fraction, linkage analysis, 88–91
Record linkage, developmental epidemiology, case-control studies, 242
Recurrence, course of disease, 226–228
Regression to mean, internal validity, 160
REGTL, segregation analysis algorithms, psychiatric genetics, 109–114
Relapse, recurrence, course of disease, 226–228
Relative risk. See also Risk association measures, 79
association tests, 44
Reliability, 131–147
binary judgments, 137–138
defined, 149
drug dependence, 493
estimation, 13–135
overview, 131–132
personality disorders, 584
population variance effect on, 135
psychiatric interview, 266
reliability coefficient, 132–133
statistical remedies for low reliability, 136–137
statistics, 138–145
ANOVA analysis (one-way), 139–141
ANOVA analysis (two-way), 141–143
Cohen’s 6, 144
Cronbach’s 7, 143
generally, 138–139
product moment correlation, 145
symptom scales and schedules, 307–311
Reliability coefficient, described, 132–133
Religion, alcohol use and abuse, 463, 465
Remission, course of disease, 224–226
Repeated cross-sectional survey, hybrid studies, 25
Repeated observations, developmental epidemiology, analytic methods, 243
Replication, reliability estimation, 133
Research Diagnostic Criteria (RDC), 262, 292, 305
major depression, 391, 392
schizophrenia, 367
Research methods. See Psychiatric epidemiologic research methods
Resilience, developmental epidemiology, 248
Response bias, reliability estimation, 134–135
Restriction Fragment Length Polymorphism, linkage analysis, 85
Retrospective cohort studies:
described, 18–19
developmental epidemiology, 241
odds ratio, 37
Rheumatoid arthritis, schizophrenia and, 374
Risk:
association measures, 79
association tests, 44
cumulative incidence, outcome occurrence measures, 56
estimation of, to relatives, 102–107
Risk factor epidemiology, historical perspective, 197
Risk factors:
bipolar disorder, 437–439
child and adolescent psychiatry, 646–650
genetics, 646–647
neighborhood and social context, 649–650
parental psychopathology, 647
prenatal factors, 648–649
socioeconomic status, 647–648
child and adolescent psychiatry (anxiety disorders), 679–685
age differences, 679–680
autonomic and psychophysioligic reactivity, 683–684
gender differences, 679
genetics and family history, 680–681
life events and stressors, 684–685
medical conditions, 682–683
perinatal influences, 682
socioeconomic status and ethnicity, 680
temperament and personality, 681–682
child and adolescent psychiatry (mood disorders), 666–672
age differences, 667
cognitive factors, 671
gender differences, 666–667
genetics, 668–670
hormonal change, 670
life events and stressors, 671–672
neurobiology, 670
socioeconomic class, race, and ethnicity, 667–668
temperament, 670–671
drug dependence, 482–483
 dysthymic disorder, 405–406
geriatric psychiatry:
comorbidity, 614–615
dementing disorders, 613–614
depression, 397398, 612–613
major depression, 395–403
adolescent depression, 398
attributable risk, 402–405
comorbidity, 401–402
family history, 402
gender differences, 395–396
marital status, 401
race and ethnicity, 399
secular/temporal effects, 396–397
socioeconomic status, 399–400
urban-rural residence, 400
obsessive-compulsive disorder, 417
panic disorder, 409–410
social phobia, 415
study designs, 9
Rural place of birth, schizophrenia, 375. See also Urban-rural residence
Sampling:
psychiatric genetics, 99–102
reliability and, 135
survey sampling, cross-sectional studies, 13–15
Sanitary Era, 196–197
Scales. See Symptom scales and schedules
Schedule for Affective Disorders and Schizophrenia (SADS):
bipolar disorder, 434
child and adolescent psychiatry, 675
ccontent validity, 151
major depression, 391–392, 399
personality disorders, 566, 572
reliability and validity, 308, 309
symptom scales and schedules, 292–293, 305
Schedule of Affective Disorders and Schizophrenia, Epidemiological Version (K-SADS-E), 634
Schedules. See Symptom scales and schedules
Schedules for Clinical Assessment in Neuropsychiatry (SCAN), 297, 298, 307, 310, 311
Schizoaffective disorder, schizophrenia and, 374
Schizoid personality disorder, prevalence, 570
Schizophrenia, 365–387
adoption studies, 77
ascertainment bias, 100, 102
bipolar disorder and, 428
course and predictors, 378–379
defined, 368
demography, 370–373
gender and age, 372–373
marital status, 373
Schizophrenia (Continued)
  race and ethnicity, 371–372
  social class, 370–371
developmental epidemiology, 244–245
diagnosis, 137
familial disorders, 69
future directions, 380
levels of causation, 203–204
linkage analysis, 87, 93
mania and, 445, 453
methodology, 366–368
outcome investigations, 151
overview, 365
precipitating factors, 37–38
predisposing factors, 373–377
autoimmune disease, 374
family history and genetics, 373–374
obstetric, birth and early childhood factors, 375–377
season of birth, 374–375
urban versus rural place of birth, 375
psychiatric genetics, mode of transmission, 82
rates, 368–370
incidence, 369–370
prevalence, 368–369
twin studies, 66, 76
Schizotypal personality disorder:
  prevalence, 572–573
  schizophrenia and, 374
Season of birth, schizophrenia, 374–375
Sector interactions, mental health services
  research, analytic studies, 172
Secular/temporal effects, major depression, 396–397
Sedative-hypnotics, adverse effects,
  psychopharmacoepidemiology, 185–186
Segregation analysis, mode of transmission, psychiatric genetics, 78
Segregation analysis algorithms, psychiatric genetics, 109–114
Selection bias:
  developmental epidemiology, case-control studies, 242
  nonexperimental (observational) studies, group comparisons in, 27
Selection-drift hypothesis, schizophrenia, 371
Selection effects, internal validity, 160
Selective serotonin reuptake inhibitors (SSRIs), adverse effects,
  psychopharmacoepidemiology, 186
Self-report instruments, criterion validity, 153
Self-report questionnaire, personality disorders, data sources, 588–589
Services, child and adolescent psychiatry, 629–630
Service use estimates, population surveys, mental health services research, 169
Service utilization, National Comorbidity Survey, baseline results, 350–351
SIMLINK (software program), linkage analysis, 94
Simple random sampling, survey sampling, 14–15
Single ascertainment, psychiatric genetics, 101
Single nucleotide polymorphisms, linkage analysis, 86
Single stranded conformational polymorphisms, psychiatric genetics, 98–99
Skin cancer, segregation analysis, 114
Social Adjustment Interview Schedule, content validity, 151
Social costs:
  child and adolescent psychiatry, 630
  National Comorbidity Survey, baseline results, 350
Social phobia, 414–415
defined, 414
rates of, 414–415
risk factors, 415
Socioeconomic status:
  alcohol use and abuse, 462, 463
  bipolar disorder, 438
  child and adolescent psychiatry, 647–648
  anxiety disorders, 680
  mood disorders, 667–668
  major depression, 399–400
  schizophrenia, 370–371
Sociological model, clinical model and, alcohol use and abuse, 465–466
Spearman-Brown formula, statistical remedies for low reliability, 136, 137, 143
Specificity, internal validity, 159
Speed of remission, defined, 226
Standardized Psychiatric Examination (SPE), personality disorders, 565
Statistical regression artifacts, internal validity, 159–160
Statistical remedies, for low reliability, 136–137
Steppingstone association, drug dependence, 498
Stirling Study, 290
Stress:
  child and adolescent psychiatry (anxiety disorders), 684–685
  child and adolescent psychiatry (mood disorders), 671–672
  schizophrenia, 377
Structured interview, personality disorders, data sources, 587–588
Study designs, 926
  developmental epidemiology, 240–242 (See also Developmental epidemiology)
  experimental studies, 10–12
generally, 9–10
  nonexperimental (observational) studies, 12–26
  (See also Nonexperimental (observational) studies)
Substance abuse. See also Alcohol use and abuse; Drug dependence
first-onset mania, 453–454  
schizophrenia, 377–378  
Subsyndromal depression, geriatric psychiatry, 609–610  
Suicide:  
child and adolescent psychiatry (mood disorders), 673  
geriatric psychiatry, 619  
Surveys, psychopharmacoepidemiology, data sources, 184–185  
Survey sampling, cross-sectional studies, 13–15  
Survival, cumulative incidence, outcome occurrence measures, 56  
Symptom Checklist 90-items SCL-90, 304  
Symptom scales and schedules, 273–332 dimensions and syndromes, 275–279  
clinical instruments (primary care settings), 299–302  
clinical instruments (U.K. and WHO), 296–298  
clinical instruments (U.S.), 302–306  
epidemiologic instruments (U.K.), 306–307  
epidemiologic instruments (U.S. and Canada), 288–296  
epidemiologic instruments (WHO), 298–299  
generally, 283–286  
World War II, 286–288  
measurements, 311–314, 315–316  
overview, 273–274, 281–283  
reliability and validity, 307–311, 316–318  
clinician-administered structured interviews, 311  
lay-administered diagnostic schedules, 309–311  
symptom scales, 307–309  
technical developments, 281  
Syndromes, dimensions and, symptom scales and schedules, 275–279  
Tobacco dependence:  
prevalence, 505–506  
twin studies, 525  
Tolerance, alcoholism, 466  
Tourette’s syndrome, psychiatric genetics, mode of transmission, 82  
Transmission test for linkage, psychiatric genetics, 97–98  
Tridimensional Personality Questionnaire (TPQ), content validity, 151–152  
Truncate ascertainment, psychiatric genetics, 100  
Tuberculosis, psychiatric genetics, mode of transmission, 82  
Twenty-Two Item Scale (22IS), symptom scales and schedules, 300  
Twin studies:  
bipolar disorder, 440  
child and adolescent psychiatry, 646–647  
anxiety disorders, 681, 684  
mood disorders, 669  
drug dependence, 522–526  
family-study designs, 107–108  
gene/environment interaction, 74–76  
major depression, 402  
personality disorders, 566–567  
psychiatric genetics, 66  
schizophrenia, 373  
Two-way ANOVA analysis, reliability statistics, 141–143  
Unipolar mania. See First-onset mania  
U.S. Food and Drug Administration (FDA), 182  
Urban-rural residence:  
bipolar disorder, 437–438  
dysthymic disorder, 406  
major depression, 400  
schizophrenia, 375  
Variable number of tandem repeats (VNTRs), linkage analysis, 85
Variables, relationships between, validity of, 158–161
Violence:
  alcoholism, 467
  developmental epidemiology, 247
  drug dependence, 499
  mental illness and, levels of causation, 205–206
Viral infection, schizophrenia, 376
Withdrawal, drug dependence, 489
World Health Organization (WHO). See also
  Composite International Diagnostic Interview (CIDI); International Classification of Diseases (ICD)